NEUP · XBRL financial data
Neuphoria Therapeutics financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NEUP's year ends in late June)
| In millions of dollars | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 | †Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 16 | 1 |
| Revenue from contracts with customers | — | — | — | 16 | — |
| Research and development | — | 13 | 9 | 9 | — |
| General and administrative | — | 9 | 8 | 8 | 7 |
| Total operating expenses | — | 22 | 18 | 17 | 18 |
| Operating income (loss) | — | (22) | (18) | (1) | (16) |
| Interest income | — | 0 | 0 | 0 | 1 |
| Income tax expense (benefit) | — | (0) | (0) | (0) | (0) |
| Net income (loss) | — | (21) | (15) | (0) | (13) |
| Earnings per share, basic USD per share | — | (0.02) | (0.01) | (0.23) | (3.06) |
| Earnings per share, diluted USD per share | — | (0.02) | (0.01) | (0.23) | (3.06) |
| Weighted average shares, basic millions of shares | — | 1,469 | 1,798 | 2 | 4 |
| Weighted average shares, diluted millions of shares | — | 1,469 | 1,798 | 2 | 4 |
| Revenue millions of AUD | 0 | 0 | — | — | — |
| Research and development millions of AUD | 16 | 20 | — | — | — |
| Profit (loss) millions of AUD | (22) | (32) | — | — | — |
| Earnings per share, basic AUD per share | (0.02) | (0.02) | — | — | — |
| Earnings per share, diluted AUD per share | (0.02) | (0.02) | — | — | — |
- † Share count changed about 1/1322 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (NEUP's year ends in late June)
| In millions of dollars | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 | †Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 23 | 12 | 13 | 14 | 20 |
| Accounts receivable | — | 0 | 0 | 0 | 1 |
| Total current assets | — | 13 | 13 | 15 | 21 |
| Property and equipment, net | — | 0 | 0 | 0 | — |
| Right-of-use asset | — | 0 | 0 | 0 | — |
| Goodwill | 9 | 9 | 9 | 9 | 3 |
| Total assets | — | 29 | 28 | 29 | 29 |
| Accounts payable | — | 1 | 2 | 1 | 0 |
| Total current liabilities | — | 3 | 4 | 4 | 1 |
| Lease liability, non-current | — | 0 | 0 | — | — |
| Total liabilities | — | 7 | 10 | 10 | 4 |
| Accumulated deficit | — | (162) | (178) | (178) | (192) |
| Total stockholders' equity | 39 | 22 | 17 | 19 | 25 |
| Total liabilities and equity | — | 29 | 28 | 29 | 29 |
| Common shares outstanding (cover page) millions of shares | 1,353 | 1,487 | 3,118 | 2 | 5 |
| Cash and cash equivalents millions of AUD | 34 | 18 | — | — | — |
| Total current assets millions of AUD | 42 | 20 | — | — | — |
| Total assets millions of AUD | 65 | 43 | — | — | — |
| Total current liabilities millions of AUD | 3 | 4 | — | — | — |
| Total liabilities millions of AUD | 8 | 10 | — | — | — |
| Total equity millions of AUD | 57 | 33 | — | — | — |
- † Share count changed about 1/1322 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (NEUP's year ends in late June)
| In millions of dollars | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 | †Jun 30, 2025 | Jun 30, 2026 |
|---|---|---|---|---|---|
| Net income (loss) | — | (21) | (15) | (0) | (13) |
| Stock-based compensation | — | 1 | 1 | 0 | 0 |
| Net cash from operating activities | — | (15) | (15) | 0 | (12) |
| Proceeds from issuing common stock | — | — | 10 | 2 | 18 |
| Net cash from financing activities | — | 4 | 15 | 2 | 18 |
| Net change in cash | — | — | 1 | 2 | 6 |
| Net cash from operating activities millions of AUD | (22) | (21) | — | — | — |
| Net cash from investing activities millions of AUD | 1 | 0 | — | — | — |
| Net cash from financing activities millions of AUD | 27 | 6 | — | — | — |
- † Share count changed about 1/1322 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Neuphoria Therapeutics | 20 | year only | 1.2* | 5.4M | — | 10-KJun 30, 2026 |
| CV Sciences | 0.3 | 3 | 0* | 225.8M | — | 10-QJun 30, 2026 |
| Minerva Neurosciences | 25 | not reported | (13)* | 47.7M | 5.6 quarters | 10-QJun 30, 2026 |
| Sunshine Biopharma | 14 | 9.3 | (0.9)* | 3.9M | 15.0 quarters | 10-QJun 30, 2026 |
| Zeo ScientifiX | 2.3 | not reported | not reported | 7.8M | — | 10-KTJun 30, 2026 |
| Bolt Biotherapeutics | 13 | 0 | (6.5)* | 1.9M | 2.7 quarters | 10-QJun 30, 2026 |
| Intensity Therapeutics | 9.5 | not reported | (2.3)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Protagenic Therapeutics, Inc.\new | 0.6 | not reported | (0.9) | 1.8M | 0.6 quarters | 10-QJun 30, 2026 |
| Biomerica | 2.7 | 1.3 | (0.8) | 4.6M | 3.4 quarters | 10-QAug 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.